SCHEMBL1011259

SCHEMBL1011259

COC(=O)Cc1cccc(Oc2ccc(C(F)(F)F)cc2CNCS(=O)(=O)c2ccc(OC)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.45
SCN9A Q15858 4/20 0.44
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PPARG P37231 3/20 0.40
PPARD Q03181 3/20 0.40
PPARA Q07869 3/20 0.40
MAPT P10636 3/20 0.40
HTR2A P28223 2/20 0.40
SLC6A4 P31645 2/20 0.40
KCNH2 Q12809 2/20 0.40
CSNK1D P48730 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011260 0.84 PTGDR2 (0.46) PTGDR2SCN9AKCNQ3KCNQ2KDM4E
SCHEMBL1009640 0.84 PTGDR2 (0.46) PTGDR2SCN9AKCNQ3KCNQ2KDM4E
SCHEMBL1944279 0.82 BMP1 (0.47) PTGDR2SCN9ALMNASMN1; SMN2MAPT
SCHEMBL1062373 0.82 KCNQ3 (0.47) PTGDR2KCNQ3KCNQ2KDM4EMEN1
SCHEMBL1008886 0.82 SLC6A4 (0.57) PTGDR2KCNQ3KCNQ2KDM4EMEN1
SCHEMBL1009883 0.78 PTGDR2 (0.48) PTGDR2SCN9AKCNQ3KCNQ2KDM4E
SCHEMBL1010903 0.77 PTGDR2 (0.53) PTGDR2
SCHEMBL1943761 0.76 PTGDR2 (0.46) PTGDR2KCNQ3KCNQ2MEN1KMT2A
SCHEMBL1009651 0.76 KCNQ3 (0.46) PTGDR2SCN9AKCNQ3KCNQ2LMNA
SCHEMBL1943683 0.75 MAPT (0.44) PTGDR2SCN9AKCNQ3KCNQ2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426449-B2 Aminoalkylphenyl antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2013-04-23 US disclosed
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2011-06-02 US disclosed
EP-2268611-A2 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130453-A1 AMINOALKYLPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 PTGDR2 2/4885SCN9A 3411/4885KCNQ3 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.